ReviewInternal and emergency medicine2016
Acute bacterial skin and skin structure infections in internal medicine wards: old and new drugs.
Review in Internal and emergency medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Efficacy and safety of omadacycline for treating complicated skin and soft tissue infections: a meta-analysis of randomized controlled trials.BMC infectious diseases · 2024Pooled it
- Omadacycline for Acute Bacterial Skin and Skin Structure Infections.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Trial
- Efficacy, Safety, and Tolerability of Gepotidacin (GSK2140944) in the Treatment of Patients with Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections.Antimicrobial agents and chemotherapy · 2017Trial
- Managing skin infections in burn patients: principles and pitfalls.Current opinion in infectious diseases · 2026Review
- The Dermatology Fast Track as a Model for Integrated Care Pathways Between Emergency Medicine and Outpatient Specialty Services.Medicina (Kaunas, Lithuania) · 2025Article
- The future approach for the management of acute bacterial skin and skin structure infections.Current opinion in infectious diseases · 2025Review
- Novel Triazeneindole Antibiotics: Synthesis and Hit-to-Lead Optimization.International journal of molecular sciences · 2025Article
- Cost analysis of dalbavancin versus standard of care for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in two Italian hospitals.JAC-antimicrobial resistance · 2023Article
- What COVID-19 taught us: New opportunities and pathways from telemedicine and novel antiseptics in wound healing.International wound journal · 2022Article
- Daptomycin Population Pharmacokinetics in Patients Affected by Severe Gram-Positive Infections: An Update.Antibiotics (Basel, Switzerland) · 2022Article
- Article
- Lipid Nanoparticulate Drug Delivery Systems: Recent Advances in the Treatment of Skin Disorders.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Determination of Delafloxacin in Pharmaceutical Formulations Using a Green RP-HPTLC and NP-HPTLC Methods: A Comparative Study.Antibiotics (Basel, Switzerland) · 2020Article
- Simple and Accurate HPTLC-Densitometric Method for Quantification of Delafloxacin (A Novel Fluoroquinolone Antibiotic) in Plasma Samples: Application to Pharmacokinetic Study in Rats.Antibiotics (Basel, Switzerland) · 2020Article
- Development of Lipomer Nanoparticles for the Enhancement ofPharmaceutics · 2020Article
- Anti-Inflammatory Activity of Miodesin™: Modulation of Inflammatory Markers and Epigenetic Evidence.Oxidative medicine and cellular longevity · 2020Article
- Tedizolid Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection: A Systematic Review and Meta-Analysis.Antibiotics (Basel, Switzerland) · 2019Article
- Early discharge criteria in patients with acute bacterial skin and skin structure infections in a large tertiary-care teaching hospital in Florence, Italy.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2019Article
- Identifying patients with acute bacterial skin and skin structure infection who need blood cultures.Internal and emergency medicine · 2019Article
- Management of acute bacterial skin and skin structure infections with a focus on patients at high risk of treatment failure.Therapeutic advances in infectious disease · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skin and soft tissue infections (SSTIs) are a common cause of hospital admission among elderly patients, and traditionally have been divided into complicated and uncomplicated SSTIs. In 2010, the FDA provided a new classification of these infections, and a new category of disease, named acute bacterial skin and skin structure infections (ABSSSIs), has been proposed as an independent clinical entity. ABSSSIs include three entities: cellulitis and erysipelas, wound infections, and major cutaneous abscesses This paper revises the epidemiology of SSTIs and ABSSSIs with regard to etiologies, diagnostic techniques, and clinical presentation in the hospital settings. Particular attention is owed to frail patients with multiple comorbidities and underlying significant disease states, hospitalized on internal medicine wards or residing in nursing homes, who appear to be at increased risk of infection due to multi-drug resistant pathogens and treatment failures. Management of ABSSSIs and SSTIs, including evaluation of the hemodynamic state, surgical intervention and treatment with appropriate antibiotic therapy are extensively discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.